ETF Holdings Breakdown of SRDX

SRDX institutional holdings

The adjusted close for SRDX on 2025-11-13 was 41.41

The following institutional investment holdings of SRDX have been identified

Date	ETF ISIN/Name	Num Shares	Book value	Derived Price per Share	Comment
2025-11-13	IE00BMX0DF60 (iShares US Medical Devices UCITS ETF)	1,950	USD 80,750	41.41
Total =		1,950	USD 80,750

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with SRDX

Surmodics (NASDAQ:SRDX) Trading 8.7% Higher on Earnings Beat

Surmodics, Inc. (NASDAQ:SRDX – Get Free Report) rose 8.7% during trading on Monday after the company announced better than expected quarterly earnings. The stock traded as high as $38.33 and last traded at $38.48. Approximately 194,800 shares traded hands during mid-day trading, an increase of 10% from the average daily volume of 176,503 shares. The […] - 2025-08-13 02:22:56

Surmodics (NASDAQ:SRDX) Receives “Market Perform” Rating from Barrington Research

Barrington Research reiterated their market perform rating on shares of Surmodics (NASDAQ:SRDX – Free Report) in a research note published on Monday,Benzinga reports. Separately, Needham & Company LLC reiterated a “hold” rating on shares of Surmodics in a research note on Wednesday, April 30th. Read Our Latest Stock Report on Surmodics Surmodics Trading Up 7.3% […] - 2025-08-12 04:47:07

Wells Fargo & Company MN Raises Holdings in Surmodics, Inc. (NASDAQ:SRDX)

Wells Fargo & Company MN increased its position in shares of Surmodics, Inc. (NASDAQ:SRDX – Free Report) by 40.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 7,032 shares of the company’s stock after buying an additional 2,041 shares during the quarter. Wells Fargo & Company MN’s holdings in Surmodics were worth $278,000 […] - 2025-05-07 04:52:54

Marshall Wace LLP Purchases 19,635 Shares of Surmodics, Inc. (NASDAQ:SRDX)

Marshall Wace LLP increased its position in Surmodics, Inc. (NASDAQ:SRDX – Free Report) by 231.0% in the 4th quarter, Holdings Channel reports. The firm owned 28,135 shares of the company’s stock after buying an additional 19,635 shares during the quarter. Marshall Wace LLP’s holdings in Surmodics were worth $1,114,000 as of its most recent filing […] - 2025-04-30 04:59:02

Barclays PLC Buys 19,251 Shares of Surmodics, Inc. (NASDAQ:SRDX)

Barclays PLC grew its stake in shares of Surmodics, Inc. (NASDAQ:SRDX – Free Report) by 21.7% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 108,001 shares of the company’s stock after buying an additional 19,251 shares during the period. Barclays PLC […] - 2025-04-28 05:01:23

Surmodics (NASDAQ:SRDX) Upgraded at Lake Street Capital

Lake Street Capital upgraded shares of Surmodics (NASDAQ:SRDX – Free Report) from a hold rating to a buy rating in a report published on Friday morning, Marketbeat.com reports. Lake Street Capital currently has $43.00 price target on the stock. Several other equities research analysts have also recently commented on SRDX. StockNews.com started coverage on shares […] - 2025-03-10 03:56:53

New York Life Investment Management LLC Sells 2,584 Shares of Surmodics, Inc. (NASDAQ:SRDX)

New York Life Investment Management LLC decreased its position in shares of Surmodics, Inc. (NASDAQ:SRDX – Free Report) by 14.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 15,784 shares of the company’s stock after selling 2,584 shares during the quarter. New York Life Investment Management LLC’s holdings in Surmodics were worth $625,000 […] - 2025-03-05 08:04:59

Head to Head Comparison: Surmodics (NASDAQ:SRDX) vs. Neuronetics (NASDAQ:STIM)

Neuronetics (NASDAQ:STIM – Get Free Report) and Surmodics (NASDAQ:SRDX – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, earnings, risk, valuation, institutional ownership and profitability. Analyst Ratings This is a breakdown of current ratings […] - 2025-02-11 04:52:54

Back to Listing

Disclaimer